Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Aristea Therapeutics Inc.
Headquarters: San Diego, CA, United States of America
Website: N/A
Year Founded: 2018
Status: Out of Business
BioCentury | Mar 23, 2023
Management Tracks
New CFOs at Remix, Capstan
Plus: Maderis to be chair at Durect and updates from Generate and Patient Discovery Solutions
BioCentury | Feb 11, 2023
Product Development
Feb. 10 Quick Takes: Aristea dissolving after safety findings
Plus: Abecma more than triples PFS in triple-class MM, and updates from Genentech, Phathom, Blueprint and more
BioCentury | Nov 2, 2022
Management Tracks
Cox to head digital health at Pfizer
Plus Stegmeier joins Curie Bio and updates from Actinium, Lexeo and more
BioCentury | Jan 15, 2022
Management Tracks
Founder El-Hibri to retire from Emergent
Plus CEO Sandanayaka shifts to CSO at Nirogy, and updates from Angelini, Apie,
BioCentury | Aug 24, 2021
Management Tracks
Brun leaves the board at Merck
Plus: Aristea, GT, Connect, Xenon and more
BioCentury | Aug 3, 2021
Finance
Lessons from China’s market turmoil, plus Distillery on tap: a BioCentury podcast
Deals in Focus: Aristea-Arena, Kumquat-Lilly
BioCentury | Jul 27, 2021
Deals
Aristea plots path forward in rare skin disease with $63M series B, Arena deal
Arena obtains option to acquire well-funded AZ spinout after palmoplantar pustulosis readout
BioCentury | Mar 9, 2021
Product Development
Palmoplantar pustulosis pipeline: Data Byte
AnaptysBio’s Phase II miss for palmoplantar pustulosis (PPP) may indicate that overactive IL-36 signaling is not the dominant driver of the disease. The news could be a warning for
BioCentury | Oct 2, 2020
Distillery Therapeutics
Targeting CXCL1 signaling for HSV-1 encephalitis
DISEASE CATEGORY: Infectious disease
INDICATION: Encephalitis; herpes simplex virus (HSV) Inhibiting CXCL1 or its receptor, CXCR2, could treat encephalitis caused by HSV-1. In mice with HSV-1
INDICATION: Encephalitis; herpes simplex virus (HSV) Inhibiting CXCL1 or its receptor, CXCR2, could treat encephalitis caused by HSV-1. In mice with HSV-1
BioCentury | Sep 6, 2019
Company News
Management tracks: Prometheus, Step, Spero, NorthSea, Aristea, MODAG and more
Items per page:
1 - 10 of 10